PYXS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Pyxis Oncology Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.65 USD
1.5% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 40.7% above the Trend Line and sits at 36.7% of its 52-week range. The latest completed week returned 1.5%, after a 0.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is volatility with 48/100 conviction, while the latest news-sentiment score is 57/100. Near-term considerations: earnings are due in 11d.

Setup score 47 out of 100
Latest Close 2.65 USD 31 Jul 2026
1W Return 1.5% latest completed week
4W Return 0.8% short-term follow-through
12W Return -3.3% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.5% Latest completed week; four-week move 0.8%. Indicator stack 42/76 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 48/100 conviction; expected move 21.7%. News sentiment 57/100 59 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 40.7% above the Trend Line and sits at 36.7% of its 52-week range. The latest completed week returned 1.5%, after a 0.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.5812-week average 0.33

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.58Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.8% over four weeks, -3.3% over 12 weeks, and 140.9% over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W1.5%
4W0.8%
12W-3.3%
26W82.8%
52W140.9%
Active trend streak5 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.23Latest activity-pressure read.
Pressure change41.7%Four-week change in activity pressure.
Leadership8.34Latest relative-leadership reading.
RS change10.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value17/100Relative valuation strength. Underlying universe rank 84; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum95/100Medium-term price momentum. Underlying universe rank 6; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
11.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-38.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
99.8%
Gross profit retained from each unit of revenue.
Operating margin
-579.8%
Operating profit retained from revenue.
Free-cash-flow margin
-483.2%
Free cash flow generated from revenue.
Return on invested capital
-142.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
307.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
-0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

PYXS shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.17, expected move of 21.7%, and Sharemaestro trend signal active.

Conviction48/100
Expected move21.7%
Put/call volume0.17
Pressure82
Speculation0
Volatility96
Trend agreement15
Open options detail
Insider activity1 / 2

1 acquisitions and 2 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment57/100

Weighted news tone is neutral across 59 relevant articles.

21 positive · 33 neutral · 5 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move21.7%Nearest-chain priced movement where available.
52-week drawdown-52.3%Distance below the 52-week high.
13-week volatility20.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+59.3%Week of 8 May.
Worst week-16.8%Week of 15 May.
Latest week+1.5%Week of 31 Jul.

Shape of recent returns

Strong gains10
Modest gains3
Flat weeks0
Modest losses3
Sharp losses10
Recent vol20.7%13-week weekly-return volatility.
Base vol20.1%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew16.5% / -11.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape48/100

Trend, activity pressure, participation, and risk combine to a 48/100 tape read.

 Indicator analysis58/100

Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 5/12.

Activity pressure 0.58; No reversal markers Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 68; Small Cap Core rank 85 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options39/100

PYXS shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.17, expected move of 21.7%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 21.7% Sentiment57/100

Weighted news tone is neutral across 59 relevant articles.

Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis Insiders1 / 2

1 acquisitions and 2 disposals in the latest 180-day insider tape.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20262.65 USD1.5%1.88 USD2.47 USD1.238.345.0MOn
24 Jul 20262.61 USD10.6%1.83 USD2.47 USD1.288.386.2MOn
17 Jul 20262.36 USD-11.6%1.78 USD2.46 USD1.30-2.723.3MOn
10 Jul 20262.67 USD1.5%1.75 USD2.47 USD1.216.296.6MOn
3 Jul 20262.63 USD-5.1%1.80 USD2.47 USD0.877.549.8MOn
26 Jun 20262.77 USD36.5%1.85 USD2.47 USD0.5615.349.1MOff
19 Jun 20262.03 USD15.3%1.93 USD2.46 USD0.29-18.402.1MOff
12 Jun 20261.76 USD-1.1%2.03 USD2.47 USD0.34-27.151.7MOff
5 Jun 20261.78 USD-1.1%2.11 USD2.48 USD0.51-24.552.3MOff
29 May 20261.80 USD-8.2%2.18 USD2.48 USD0.77-27.152.7MOff
22 May 20261.96 USD-14.0%2.24 USD2.49 USD0.73-18.332.9MOff
15 May 20262.28 USD-16.8%2.29 USD2.50 USD0.70-3.683.6MOff
8 May 20262.74 USD59.3%2.33 USD2.51 USD0.5215.975.8MOff
1 May 20261.72 USD-9.5%2.36 USD2.51 USD0.25-22.451.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.